ImmunoGen Announces Marketing Approval For Kadcyla In EU - Quick Facts

(RTTNews) - Biotechnology company ImmunoGen, Inc. (IMGN) Wednesday announced that the European Commission has granted marketing approval for Kadcyla - trastuzumab emtansine or ado-trastuzumab emtansine in the US - in the European Union, triggering a $5 million milestone payment to the company.

ImmunoGen develops novel anticancer therapeutics using its antibody-drug conjugate or ADC technology.

Kadcyla has been approved for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin (trastuzumab) and a taxane, separately or in combination.

Patients should have either received prior therapy for locally advanced or metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy.

The approval in the EU is based on the findings in the EMILIA Phase III trial.